DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside

• The firm has initiated a global late-stage confirmatory trial of z-rostudirsen in certain patients with Duchenne muscular dystrophy.
• The newly launched study is designed to serve as the confirmatory trial needed to convert any accelerated approval into full traditional approval.
• The trial design has already been aligned with the U.S. Food and Drug Administration.

Shares of Dyne Therapeutics Inc. (DYN) climbed 8% on Wednesday, after the clinical-stage biotech company announced the initiation of its global late-stage confirmatory trial of z-rostudirsen in certain patients with Duchenne muscular dystrophy (DMD).

Dyne said it plans to submit an application seeking accelerated approval of z-rostudirsen to the U.S. Food and Drug Administration later this quarter, using data from an ongoing early-stage study. The newly launched study is designed to serve as the confirmatory trial needed to convert any accelerated approval into full traditional approval and to support marketing applications outside the United States.

DYN’s Trial Design

The new trial is a randomized, placebo-controlled, double-blind trial that will enroll approximately 90 ambulatory boys and young men ages 4 to 18. Participants will receive 20 mg/kg of z-rostudirsen or placebo every four weeks for 72 weeks, followed by an open-label extension. The primary endpoint is the change from baseline in rise-from-floor (RFF) velocity at Week 73, a clinically validated measure of muscle strength and motor function in DMD. Secondary endpoints include multiple functional measures such as 10-meter walk/run velocity and four-stair climb velocity.

The trial design has already been aligned with the U.S. Food and Drug Administration, the Waltham, Massachusetts-based clinical-stage company said. The first clinical site is now activated and open for enrollment.

DMD, a rare and progressive genetic muscle-wasting disease, affects roughly 12,000 people in the United States and 16,000 in the European Union. Z-rostudirsen is part of Dyne’s broader DMD franchise, which includes preclinical programs. The experimental therapy has received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the FDA.

What Do Retail Traders Think About DYN?

On Stocktwits, retail sentiment around DYN stayed within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.  

According to data from Koyfin, 14 of the 16 analysts covering DYN rate it Buy or higher, while two rate it Hold.

The 12-month average price target on the stock is $38.19, presenting a potential upside of about 140% from its last close.

DYN stock has risen 40% over the past 12 months. 

Read More: TSLA Stock Breaks Losing Streak: Fund Manager Says Autonomy Beats Rich Valuation

For updates and corrections, email newsroom[at]stocktwits[dot]com.